MA54648A - Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales - Google Patents

Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Info

Publication number
MA54648A
MA54648A MA054648A MA54648A MA54648A MA 54648 A MA54648 A MA 54648A MA 054648 A MA054648 A MA 054648A MA 54648 A MA54648 A MA 54648A MA 54648 A MA54648 A MA 54648A
Authority
MA
Morocco
Prior art keywords
tumor cells
wnt signaling
biparatopic polypeptides
antagonists
polypeptides antagonists
Prior art date
Application number
MA054648A
Other languages
English (en)
Inventor
Marie-Ange Buyse
Karen Cromie
Klaus-Peter Kuenkele
Stephanie Staelens
Beatrijs Strubbe
Vittoria Zinzalla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA54648A publication Critical patent/MA54648A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054648A 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales MA54648A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04

Publications (1)

Publication Number Publication Date
MA54648A true MA54648A (fr) 2021-11-10

Family

ID=54782606

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43368A MA43368B1 (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
MA054648A MA54648A (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43368A MA43368B1 (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Country Status (33)

Country Link
US (2) US10597449B2 (fr)
EP (2) EP3797790A1 (fr)
JP (2) JP6728355B2 (fr)
KR (1) KR102802241B1 (fr)
CN (1) CN108289943B (fr)
AR (1) AR106949A1 (fr)
AU (1) AU2016363787B2 (fr)
BR (1) BR112018010537A2 (fr)
CL (1) CL2018001384A1 (fr)
CO (1) CO2018005680A2 (fr)
CY (1) CY1123454T1 (fr)
DK (1) DK3383425T3 (fr)
EA (1) EA201891331A1 (fr)
ES (1) ES2821099T3 (fr)
HR (1) HRP20201528T1 (fr)
HU (1) HUE051777T2 (fr)
IL (1) IL259119B (fr)
LT (1) LT3383425T (fr)
MA (2) MA43368B1 (fr)
MX (1) MX380414B (fr)
MY (1) MY200933A (fr)
PE (1) PE20181515A1 (fr)
PH (1) PH12018501155B1 (fr)
PL (1) PL3383425T3 (fr)
PT (1) PT3383425T (fr)
RS (1) RS60823B1 (fr)
SA (1) SA518391728B1 (fr)
SG (1) SG11201804510PA (fr)
SI (1) SI3383425T1 (fr)
TW (1) TWI734719B (fr)
UA (1) UA122079C2 (fr)
WO (1) WO2017093478A1 (fr)
ZA (1) ZA201802867B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693476B1 (fr) 2012-02-28 2023-10-18 Novartis AG Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43
KR102317574B1 (ko) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
PH12018501155B1 (en) * 2015-12-04 2024-06-28 Boehringer Ingelheim Int Biparatopic polypeptides antagonizing wnt signaling in tumor cells
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11033636B2 (en) * 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
CN111491655A (zh) 2017-08-07 2020-08-04 加利福尼亚大学董事会 用于生成安全细胞治疗剂的平台
WO2019108806A1 (fr) * 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions et méthodes pour une cancérothérapie
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
DK3820906T3 (da) * 2018-07-05 2025-12-15 Surrozen Operating Inc Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
WO2020080941A1 (fr) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anticorps anti-protéine 5/6 associée au récepteur de lipoprotéines de faible densité
CN113661178A (zh) 2019-03-29 2021-11-16 勃林格殷格翰国际有限公司 抗癌组合疗法
EP3946617A1 (fr) 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Polythérapie anticancéreuse
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
EP3966338A1 (fr) * 2019-05-08 2022-03-16 Inhibrx, Inc. Immunothérapies ciblant cd123
MX2022001947A (es) * 2019-08-14 2022-06-14 Modmab Therapeutics Inc Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
AU2020331424A1 (en) * 2019-08-14 2022-03-31 Antlera Therapeutics Inc. Antibodies that bind to LRP6 proteins and methods of use
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (fr) * 2020-02-14 2021-08-19 University Of Washington Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable
EP4314075A4 (fr) 2021-03-24 2025-04-09 Twist Bioscience Corporation Banques d'acides nucléiques variants pour cd3
JPWO2023286854A1 (fr) * 2021-07-16 2023-01-19
AU2023421423A1 (en) * 2023-01-05 2025-07-17 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1803730A1 (fr) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Proteines de fusion d'albumine
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
CA2484556A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
EP2267032A3 (fr) 2002-11-08 2011-11-09 Ablynx N.V. Procédé d'administration de polypeptides thérapeutiques et polypeptides correspondants
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
WO2007140410A2 (fr) * 2006-05-30 2007-12-06 Van Andel Research Institute Récepteur 6 des lipoprotéines à faible densité (lrp6) utilisé en tant que marqueur de cellules souches mammaires et procédés associés
CN102537051B (zh) 2006-06-08 2014-11-26 日本精工株式会社 具有密封圈的冲压外圈滚针轴承及其制造方法
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
AU2008320823B2 (en) 2007-11-02 2013-01-17 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EP2247616A2 (fr) 2008-03-05 2010-11-10 Ablynx N.V. Nouveaux complexes dimères de fixation à des antigènes, procédés de fabrication et utilisations associés
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
CA2777527C (fr) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Procede pour faire baisser l'immunogenicite
EP2531523A1 (fr) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capables de se lier à la sérumalbumine, et composés, constructions, et polypeptides comprenant de tels peptides
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
RU2587625C2 (ru) 2010-03-24 2016-06-20 Дженентек, Инк. Анти-lrp6 антитела
MA34287B1 (fr) * 2010-05-06 2013-06-01 Novartis Ag Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
WO2011138392A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
CN103270045A (zh) * 2010-10-20 2013-08-28 霍夫曼-拉罗奇有限公司 用于调控wnt途径的方法和组合物
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY34254A (es) 2011-08-17 2013-04-05 Glaxo Group Ltd Proteínas y péptidos modificados.
WO2013067355A1 (fr) 2011-11-04 2013-05-10 Novartis Ag Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
EP2888279A1 (fr) * 2012-08-22 2015-07-01 Glaxo Group Limited Anticorps anti-lrp6
PH12018501155B1 (en) * 2015-12-04 2024-06-28 Boehringer Ingelheim Int Biparatopic polypeptides antagonizing wnt signaling in tumor cells

Also Published As

Publication number Publication date
AU2016363787B2 (en) 2023-02-02
HRP20201528T1 (hr) 2020-12-11
ZA201802867B (en) 2026-03-25
NZ742037A (en) 2025-07-25
IL259119B (en) 2022-04-01
IL259119A (en) 2018-06-28
UA122079C2 (uk) 2020-09-10
US10597449B2 (en) 2020-03-24
SA518391728B1 (ar) 2022-03-28
US20200199222A1 (en) 2020-06-25
CN108289943A (zh) 2018-07-17
BR112018010537A2 (pt) 2018-11-13
HUE051777T2 (hu) 2021-03-29
EA201891331A1 (ru) 2018-12-28
JP6728355B2 (ja) 2020-07-22
WO2017093478A1 (fr) 2017-06-08
CY1123454T1 (el) 2022-03-24
EP3383425B1 (fr) 2020-07-15
HK1255725A1 (en) 2019-08-23
MA43368A (fr) 2018-10-10
TW201731868A (zh) 2017-09-16
TWI734719B (zh) 2021-08-01
CO2018005680A2 (es) 2018-06-12
CN108289943B (zh) 2023-06-20
MA43368B1 (fr) 2020-09-30
PT3383425T (pt) 2020-10-07
EP3797790A1 (fr) 2021-03-31
KR102802241B1 (ko) 2025-05-07
CA3006235A1 (fr) 2017-06-08
AU2016363787A1 (en) 2018-05-17
JP2019506841A (ja) 2019-03-14
MX2018006760A (es) 2018-08-01
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
PH12018501155A1 (en) 2019-01-28
CL2018001384A1 (es) 2018-09-14
PL3383425T3 (pl) 2021-01-11
ES2821099T3 (es) 2021-04-23
RS60823B1 (sr) 2020-10-30
LT3383425T (lt) 2020-10-12
PE20181515A1 (es) 2018-09-21
US20170174762A1 (en) 2017-06-22
JP2020178701A (ja) 2020-11-05
SI3383425T1 (sl) 2020-11-30
US11952418B2 (en) 2024-04-09
DK3383425T3 (da) 2020-09-28
MX380414B (es) 2025-03-12
SG11201804510PA (en) 2018-06-28
AR106949A1 (es) 2018-03-07
EP3383425A1 (fr) 2018-10-10
KR20180081825A (ko) 2018-07-17

Similar Documents

Publication Publication Date Title
MA54648A (fr) Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
MA47580A (fr) Cellules immunitaires bipartites et tripartites de signalisation
EP3377078A4 (fr) Vésicules extracellulaires de cellules neurales
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
DK3560953T3 (da) Celle
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
MA48760A (fr) Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
HUE052099T2 (hu) Indol származékok felhasználásra az orvostudományban
HRP20190600T1 (hr) Postupak za neinvazivnu procjenu genetičkih varijacija
EP3508222A4 (fr) Médicament pour éliminer des cellules vieillissantes
PL3151327T3 (pl) Roztwór elektrolitu
DK2971082T3 (da) Ikke-invasiv prænatal screening
EP3544623A4 (fr) Séquences peptidiques pénétrant dans des cellules
DK3254325T3 (da) Elektrolytdannelsesfremgangsmåde
DK3254326T3 (da) Elektrolytdannelsesfremgangsmåde
DK3169232T3 (da) Intermitterende måling af partialtrykket af en analyt i hudvæv
DK3209323T3 (da) Forbedret koaguleringssammensætning
EP4012023C0 (fr) Thérapie de cellules souches dans des pathologies endométriales
EP3191581C0 (fr) Mutagenèse ciblée dans la spiruline
EP3516080A4 (fr) Constructions pour la surveillance en continu de cellules vivantes
FR3023067B1 (fr) Cellules tandem multifils
CL2015000372S1 (es) Telefono celular
EP3359675A4 (fr) Activation des voies de signalisation immunitaires dans des cellules par optoinfection
EP3145533C0 (fr) Compositions destinées à favoriser la cicatrisation des plaies
EP3545960A4 (fr) Composé multivitaminé stimulant l'appareil digestif